The results indicated that BRINP3 functions as an oncogene within osteosarcoma through MAP4 and thus could be used as a potential biomarker for the diagnosis and treatment of osteosarcoma (Parker et al. 2014). The gene discussed is MAP4; the disease is osteosarcoma.